You're blaming management for not getting FINRA to halt trading when they only do that for rare occasions like overseas corporate actions on an ADR that's traded OTC. They simply would never halt NWBO because data was being presented by a trial researcher at a private scientific meeting. It's nonsensical and anti free market to suggest that would be a realistic possible outcome.